advertising
-
1.
Mendoza, FA, CM Artlett, N Sandorfi, et al. :Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. .Semin Arthritis Rheum 35::238. ,2006. .
-
2.
Miskulin, D, A Gul, MR Rudnick, et al. :Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure. .Up-to-date online 17.3 .Available at: http://uptodateonline.com/online/content/topic.do?topicKey=dialysis/48700&selectedTitle=1%7E77&source=search_result. .Accessed November 21, 2009.
-
3.
Galan, A, SE Cowper, and R Bucala. :Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). .Curr Opin Rheumatol 18::614. ,2006. .
-
4.
Kuo, PH, E Kanal, AK Abu-Alfa, et al. :Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. .Radiology 242::647. ,2007. .
-
5.
Cowper, SE, R Bucala, and PE Leboit. :Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis-setting the record straight. .Semin Arthritis Rheum 35::208. ,2006. .
-
6.
Moschella, SL, J Kay, BT Mackool, et al. :Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skin. .N Engl J Med 351::2219. ,2004. .
-
7.
Cowper, SE, R Bucala, and PE LeBoit. :Case 35-2004: nephrogenic fibrosing dermopathy. .N Engl J Med 352::1723. ,2005. .
-
8.
Swartz, RD, LJ Crofford, SH Phan, et al. :Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. .Am J Med 114::563. ,2003. .
-
9.
Sadowski, EA, LK Bennett, MR Chan, et al. :Nephrogenic systemic fibrosis: risk factors and incidence estimation. .Radiology 243::148. ,2007. .
-
10.
High, WA, RA Ayers, J Chandler, et al. :Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. .J Am Acad Dermatol 56::21. ,2007. .
-
11.
Boyd, AS, JA Zic, and JL Abraham. :Gadolinium deposition in nephrogenic fibrosing dermopathy. .J Am Acad Dermatol 56::27. ,2007. .
-
12.
High, WA, RA Ayers, and SE Cowper. :Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. .J Am Acad Dermatol 56::710. ,2007. .
-
13.
Schroeder, JA, C Weingart, B Coras, et al. :Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. .Clin J Am Soc Nephrol 3::968. ,2008. .
-
14.
Cowper, SE . :The International Center for Nephrogenic Fibrosing Dermopathy Research .Available at: http://www.icnfdr.org. .Accessed November 21, 2009.
-
15.
Cowper, SE . :Nephrogenic fibrosing dermopathy: the first 6 years. .Curr Opin Rheumatol 15::785. ,2003. .
-
16.
Marckmann, P, L Skov, K Rossen, et al. :Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. .J Am Soc Nephrol 17::2359. ,2006. .
-
17.
Grobner, T . :Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21::1104. ,2006. .
-
18.
Daram, SR, CM Cortese, and B Bastani. :Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. .Am J Kidney Dis 46::754. ,2005. .
-
19.
Evenepoel, P, M Zeegers, S Segaert, et al. :Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. .Nephrol Dial Transplant 19::469. ,2004. .
-
20.
Kafi, R, GJ Fisher, T Quan, et al. :UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. .Arch Dermatol 140::1322. ,2004. .
-
21.
Kucher, C, J Steere, R Elenitsas, et al. :Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. .J Am Acad Dermatol 54::S31. ,2006. .
-
22.
Gibson, SE, CF Farver, and RA Prayson. :Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. .Arch Pathol Lab Med 130::209. ,2006. .
-
23.
Kucher, C, X Xu, T Pasha, et al. :Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema. .J Cutan Pathol 32::484. ,2005. .
-
24.
Edsall, LC, JC English 3rd, MW Teague, et al. :Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy. .J Cutan Pathol 31::247. ,2004. .
Nephrogenic Systemic Fibrosis in the Podiatric Patient
Search for other papers by Lewis Freed in
Current site
Google Scholar
PubMed
Search for other papers by Josh Hill in
Current site
Google Scholar
PubMed
Search for other papers by David Gooch in
Current site
Google Scholar
PubMed
Nephrogenic systemic fibrosis (NSF) is a severely debilitating disease that was first described in the literature by Cowper and colleagues in 2000. It is pertinent to the field of podiatry because patients with NSF first manifest cutaneous symptoms in the lower extremity in the form of fibrosing lesions. To date, these lesions have been documented only in people with moderate to severe kidney failure. There is speculation that gadolinium, used as a contrast agent for imaging, might be the inciting factor that triggers a cascade of events that results in the inappropriate fibrosis both in the dermis and in deeper tissues. Nephrogenic systemic fibrosis has been shown to cause these lesions in the lungs, pleura, diaphragm, myocardium, pericardium, and dura mater, the presence of which are typically indicative of severe progression of NSF. In cases where the lesions are manifest in the periarticular tissue, joint contractures and restricted range of motion can often result. We provide a quick synopsis of NSF, and a short case study that describes the authors’ experience with one of their patients who requested a surgical consult as a result of being wheelchair-bound due to NSF’s sequelae. (J Am Podiatr Med Assoc 102(5): 419-421, 2012)
advertising
